# Vasoconstriction Trial With LEO 90100 Aerosol Foam

> **NCT02973776** · PHASE1 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 36 (actual)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **DRUG:** LEO 90100 aerosol foam
- **DRUG:** Dermoval®/Dermovate®
- **DRUG:** Diprosone
- **DRUG:** Elocon
- **DRUG:** Locoid
- **OTHER:** LEO 90100 foam vehicle

## Key facts

- **NCT ID:** NCT02973776
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02973776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02973776, "Vasoconstriction Trial With LEO 90100 Aerosol Foam". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02973776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*